InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,978.00
(
-1.19%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.17
(
-0.12%
)
Bitcoin
60,656.11
(
0.65%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 183

Saturday, 06/02/2018 3:55:25 PM

Saturday, June 02, 2018 3:55:25 PM

Post# of 438
CORT 3/18 court filings against TEVA will put a stay on ANDA approval for cash crop Korlym

CORT develops treatments designed to modulate cortisol receptors located throughout the body.

CORT has a library of ~300 pre-clinical glucocorticoid receptor modulators

Lead developmental compound, relacorilant, will enter Ph3 EOY/18.

If CORT can get relacorilant to market before TEVA's Korlym analog reaches the market, this stock will have significant upside.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up